.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Breast Cancer

Payer Perspective of Coverage on Cancer Therapies

The role of PI3 kinase inhibition in various settings in metastatic breast cancer and a payer perspective on differentiating breast cancer at various stages of disease progression.

Payer Coverage on Repeat Biopsy in MBC

Testing patients who have received CDK4/6 inhibitors in metastatic breast cancer (MBC) as well as testing patients with ctDNA upon disease progression with a single gene test versus NGS.

Dr Debra Patt Addresses the Importance of Cancer Screening Awareness, Strong Health Care Infrastructure

May 11th 2022, 9:17pm

Video

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how community oncology practices have heightened their outreach efforts to entice patients back in for cancer screenings and the importance of thinking outside the box to overcome staffing shortages in the oncology space.

Ribociclib Data Show Reduced Mortality Risk in HR+/HER2- Advanced Breast Cancer

May 9th 2022, 2:02pm

Article

Officials from Novartis emphasized that the ribociclib-fulvestrant combination is the only one in the CDK4/6 inhibitor class to demonstrate an overall survival benefit when used in a first-line setting among postmenopausal women.

FDA Approves Enhertu for Use in Metastatic Breast Cancer

May 5th 2022, 4:57pm

Article

This approval of trastuzumab deruxtecan (Enhertu) follows the March release of data from the DESTINY-Breast03 trial on the anti-HER2 monoclonal antibody, also a HER2-directed antibody-drug conjugate, which indicated superior outcomes vs trastuzumab emtansine.

Dr Hatem Soliman Explains Short-, Long-term Treatment Priorities for Metastatic Disease

May 3rd 2022, 6:45pm

Video

The intent of metastatic disease treatment is palliative, not curative, so we try to prolong life and provide quality of life as much as we can, said Hatem Soliman, MD, medical director of the Clinical Trials Office, Moffitt Cancer Center.

Contributor: Helping Women of Color Achieve a Healthier Future

April 27th 2022, 6:43pm

Article

To achieve health equity, experts from CVS Health discuss why we must invest in programs that improve access to health care for historically marginalized communities, address social determinants, boost health education, increase representation in all levels of health care delivery, widen access to clinical trial research, and more.

Dr Hatem Soliman Addresses the Economic Burden of Metastatic Breast Cancer Treatment

April 25th 2022, 2:46pm

Video

The financial toxicity of newer metastatic breast cancer (MBC) treatments is a significant concern and requires stakeholders to work together to find the best value- and evidence-based treatments for patients, said Hatem Soliman, MD, medical director, Clinical Trials Office, Moffitt Cancer Center.

Dr Debra Patt: The True Impact of the Pandemic on Cancer Screenings, Diagnoses Is Not Yet Known

April 23rd 2022, 12:41pm

Video

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses how the pandemic may have influenced cancer screening and diagnosis rates.

Breast MRI Linked to Greater Downstream Service Use, Costs vs Mammography

April 20th 2022, 10:13pm

Article

This investigation focused on use of additional services and incidence of new diagnoses among women who underwent a breast cancer screening MRI—having a low or average risk of the cancer—compared with a matched cohort who underwent mammography.

Dr Debra Patt Discusses Considering Strategies for Additional COVID-19 Boosters in Breast Cancer

April 16th 2022, 12:54pm

Video

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses considerations for getting a second COVID-19 booster, or a fourth dose, among survivors of breast cancer or patients currently undergoing treatment as well as those who may be immunocompromised.

Choice of Breast Cancer Surgical Treatment Likely Influences Long-term QOL

April 13th 2022, 3:01pm

Article

This new study used data on women with stage 0 to II breast cancer to investigate their long-term quality of life (QOL) as it related to choice of surgery and the decision to undergo adjuvant radiation therapy.